



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

Bone Density Regulators

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:		Prescriber Name:	
Member ID Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Phone Number:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>Jefferson Health Plans' maximum approval time is 12 months but may be less depending on the criteria..</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. The request is for renewal of the Bone Density Regulator that was previously approved. If YES, go to 19. If NO, go to 2.

Yes

No

Q2. The member meets ALL of the following:

Is prescribed the Bone Density Regulator for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication

Is prescribed a dose and duration of therapy that are consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature

Does not have a contraindication to the prescribed drug

Q3. For an osteoporosis-related condition, the member was evaluated for secondary causes of osteoporosis including complete blood count, vitamin D, ionized calcium, phosphorus, albumin, total protein, creatinine, liver enzymes (specifically alkaline phosphatase), intact parathyroid hormone, thyroid stimulating hormone, urinary calcium excretion, and testosterone (if a male)

Yes

No

NA

Q4. The request is for an anabolic agent. If YES, go to 5. If NO, go to 12.

Bone Density Regulators

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q5. For an anabolic agent, has a T-score of -3.5 or below, a T-score of -2.5 or below and a history of fragility fracture, or multiple vertebral fractures. If YES, go to 7. If NO, go to 6.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q6. For an anabolic agent, has a history of therapeutic failure of or a contraindication or an intolerance to bisphosphonates.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q7. For an anabolic agent, the member has not received a cumulative treatment duration that exceeds recommendations in the FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q8. For an anabolic agent, For Forteo (teriparatide) and Tymlos (abaloparatide), the member DOES NOT have any of the following:

- a. Paget's disease,
- b. Bone metastases,
- c. A history of skeletal malignancies,
- d. Metabolic bone disease other than osteoporosis,
- e. A hypercalcemic disorder,
- f. Unexplained elevations of alkaline phosphatase,
- g. Open epiphyses,
- h. Prior external beam or implant radiation therapy involving the skeleton

<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> NA
------------------------------	-----------------------------	-----------------------------

Q9. For an anabolic agent, For Evenity (romosozumab), the member does not have a history of myocardial infarction or stroke?

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q10. For an anabolic agent, For Evenity (romosozumab) or Tymlos (abaloparatide), the member has a contraindication or an intolerance to teriparatide.

Bone Density Regulators

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> NA
------------------------------	-----------------------------	-----------------------------

Q11. For an anabolic agent, For Forteo (teriparatide) and Bonsity (teriparatide), has a contraindication or an intolerance to generic teriparatide that would not be expected to occur with the requested drug. If YES, go to 17.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q12. The request is for Evista (raloxifene). If YES, go to 13. If NO, go to 16.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q13. For Evista (raloxifene), all of the following:

<input type="checkbox"/> Does not have a history of venous thromboembolic events or breast cancer.	<input type="checkbox"/> For women with a risk factor for stroke (such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking), the increased risk of death due to stroke has been discussed with the beneficiary and documented by the prescriber.
--	--

Q14. 14. For Evista (raloxifene), The member is a postmenopausal woman at high risk of fracture² and high risk for invasive breast cancer as defined by one of the following:

- a. Prior biopsy with lobular carcinoma in situ (LCIS) or atypical hyperplasia,
- b. One or more first degree relatives with breast cancer,
- c. A 5-year predicted risk of breast cancer 1.66% (based on the modified Gail model)

If YES, go to 18. If NO, go to 15.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q15. For Evista (raloxifene), the member is a postmenopausal woman at high risk of fracture² with a history of therapeutic failure¹ of or a contraindication or an intolerance to oral bisphosphonates. If YES, go to 18.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Bone Density Regulators

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

Q16. For all other Bone Density Regulators, the request is for a denosumab 120 mg/1.7 mL product. If YES, go to 18. If NO, go to 17.

Yes

No

Q17. For all other Bone Density Regulators, the request is not for a denosumab 120 mg/1.7 mL product and all of the following:

Is at high risk of fracture,

Has a documented history of therapeutic failure¹ of or a contraindication or an intolerance to the preferred Bone Density Regulators approved or medically accepted for the beneficiary's diagnosis,

For a parenteral bisphosphonate, has a contraindication or an intolerance to oral bisphosphonates.

Q18. For a non-preferred Bone Density Regulator with a therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic that would not be expected to occur with the requested drug.

Yes

No

Q19. Based on the prescriber's assessment, the beneficiary's condition has stabilized and/or the beneficiary continues to benefit from the prescribed Bone Density Regulator.

Yes

No

Q20. For a non-preferred Bone Density Regulator with a therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent brand/generic or corresponding biosimilar/brand biologic/unbranded biologic that would not be expected to occur with the requested drug.

Yes

No

Q21. Additional Information:



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

Bone Density Regulators

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

Prescriber Signature

Date

v2026-06